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Abstract
Disturbed homocysteine metabolism is a risk factor for Alzheimer's disease (AD) and may contribute to
the disease pathophysiology by increasing both amyloid-beta (Abeta) production and phosphorylated tau
(P-tau) accumulation. Here, we evaluated the relationship between the cerebrospinal fluid (CSF)
concentrations of homocysteine (Hcys), S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH),
and 5-methyltetrahydrofolate (5-MTHF), and the markers for AD pathology, amyloid-beta
(Abeta)<formula>_{1-42}</formula> and P-tau181, in 98 cognitively healthy subjects aged 16-81 years
and 54 AD patients. In multivariate regression tests including age, gender, creatinine, and presence of
the apolipoprotein E epsilon4 allele, P-tau181 was associated with SAH (beta = 0.490; p < 0.001),
5-MTHF (beta = -0.273; p = 0.010) levels, and SAM/SAH ratio (beta = -0.319; p = 0.013) in controls,
and with SAH (beta = 0.529; p = 0.001) in AD patients. The levels of
Abeta<formula>_{1-42}</formula> were not associated with the CSF concentrations of Hcys, SAM,
SAH, or 5-MTHF neither in the AD nor in the control group. The results suggest that alteration of the
homocysteine metabolism is related to increased accumulation of phosphorylated tau and may
contribute to the neurofibrillary pathology in normal aging and in AD.
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Abstract 
Background: Disturbed homocysteine metabolism has been described as a risk factor for 
Alzheimer’s Disease (AD), and may contribute to the disease pathophysiology by increasing 
both amyloid beta (Aß) production and phosphorylated tau (P-tau) accumulation.  
Methods: In the present study we evaluated the relationship between the cerebrospinal fluid 
concentrations of homocysteine (Hcys), S-adenosylmethionine (SAM), S-
adenosylhomocysteine (SAH) and 5-methyltetrahydrofolate (5-MTHF), and the markers for 
AD pathology Aß1-42 and P-tau181 in 98 subjects without cognitive impairment aged 16-81 
years, and in 54 AD patients.  
Results: In multivariate regression tests including age, gender, creatinine, and presence of the 
APOE ε4 allele, P-tau181 was associated with SAH (ß=0.490; p<0.001), 5-MTHF (ß=-0.273; 
p=0.010) levels, and SAM/SAH ratio (ß=-0.319; p=0.013 in controls, and with SAH 
(ß=0.529; p=0.001) in AD. In the controls aged ≥50 years (n=49), P-tau181 was associated 
with SAH (ß=0.394; p=0.023) and Hcys levels (ß=0.394; p=0.005), whereas in the younger 
controls P-tau181 was associated with SAH (ß=0.441; p=0.004) and the SAM/SAH ratio 
(ß=0.477; p=0.003). The levels of Aß1-42 were not associated with the CSF concentrations of 
Hcys, SAM, SAH or 5-MTHF neither in the AD nor in the control group. 
Conclusion: The results suggest that alteration of the homocysteine metabolism is related to 
increased accumulation of phosphorylated tau, and may contribute to the neurofibrillary 
pathology in AD. This association may become relevant for the pathophysiological changes in 
AD decades before the clinical onset of the disease, and may explain in part the finding of 
altered homocysteine metabolism as a risk factor of AD.  
 
 
 
 
Introduction: 
Sporadic Alzheimer disease (AD) is the most common cause of dementia in the elderly. 
Neuropathological changes as the progressive deposition of amyloid ß protein (Aß) and the 
formation of neurofibrillary tangles consisting primarily of phosphorylated tau protein (P-tau) 
begin many years before the clinical manifestation of the disease. Related alterations of 
cerebrospinal fluid (CSF) Aß1-42 and P-tau concentrations can be detected already in 
asymptomatic older subjects at risk for AD (Sunderland, 2004), and predict cognitive decline 
in cognitively healthy older adults (Stomrud, 2007; Fagan, 2007) and in subjects with mild 
cognitive impairment (Hansson, 2006).    
 
Disturbed homocysteine/methionine metabolism as indicated by increased plasma 
homocysteine, is a common finding in the elderly (Donini, 2007), and it is associated with 
cognitive impairment and cognitive decline over time (Riggs KM, 1996; Lehmann M 1999; 
Morris MS, 2001; Ravaglia 2003; Wright CB, 2004). Several epidemiologic studies have 
found hyperhomocysteinemia to be a strong and independent risk factor for the development 
of AD dementia (Seshadri et al., 2002; Blasko et al, 2006). However, the pathophysiological 
mechanisms linking the homocysteine metabolisms and AD are not fully understood.  
 
 
In the folate and vitamin B12 dependent homocysteine metabolism, methionine is activated to 
S-adenosylmethionine (SAM), which serves as ubiquitous methyl-group donor and is 
necessary e.g. for the synthesis of neurotransmitters, neuronal membrane stability and DNA 
methylation (Mudd et al., 2001; Surtees et al., 1991). The demethylated product of SAM is S-
adenosylhomocysteine (SAH), which can be hydrolyzed to the neurotoxic amino acid 
homocysteine. As these reactions are reversible, increased homocysteine levels can lead to the 
accumulation of SAH, which inhibits the transmethylation events involving SAM. Due to the 
central role of SAM as methyl group donor, and SAH as a strong inhibitor of transmethylation 
reactions, lower levels of SAM and higher levels of SAH are supposed to result in a reduced 
methylation capacity, which is represented by the SAM/SAH ratio (Finkelstein, 1998). 
Homocysteine can be excreted via the urine, or degraded to cystathionine, and, further, to 
cysteine. Alternatively, homocysteine can be remethylated to methionine by transfer of a 
methyl group from the folate derivate 5-methyltetrahydrofolate (5-MTHF).  
 
There is growing evidence from cell culture experiments and mouse models that 
homocysteine metabolism alterations may contribute to the AD pathology by increasing both 
Aß production and tau phosphorylation  (Sontag, 2007; Zhang, 2007; Chan 2008; Sontag, 
2008). 
However, only a few studies have investigated changes of the homocysteine metabolism in 
the central nervous system of patients with AD. Cerebrospinal fluid (CSF) studies on the 
association of the homocysteine metabolism with AD revealed conflicting results (Bottiglieri, 
1990; Selly, 2002, Serot, 2005) In a study on CSF levels of SAM, 5-MTHF and SAH, the 
authors found no differences between these metabolites in AD and controls (Mulder, 2005), 
whereas in another study significantly lower CSF levels of SAM were found in patients with 
AD compared to controls (Bottiglieri, 1990). In line with the finding of reduced 
concentrations of SAM in the CSF, decreased SAM levels were observed in the brains of AD 
patients (Morisson et al., 1996). Furthermore, a positive correlation was found between Aß 
and homocysteine in plasma in a study in AD and non-AD patients (Irizarry 2005), whereas a 
CSF study reported significant correlations of SAH and folate concentrations with P-tau181 
levels in participants with different neurological diseases (Obeid et al. 2007). 
 
In the present study we evaluated the relationship between different elements of the 
homocysteine metabolism and CSF markers of AD pathology. We assessed the CSF 
concentrations of Hcys, SAM, SAH and 5-MTHF as well as the levels of Aß1-42 and P-
tau181 in adults without cognitive impairment over the life span and in AD patients. 
Additionally, we determined the apolipoprotein E (APOE) genotype of the study participants.  
 
 
 
 
Methods: 
Patients 
The 54 study participants with AD were referred to the Memory Clinic, Department of 
Psychiatry, University of Bonn, for investigation of their cognitive complaints. They met 
clinical diagnostic criteria for probable AD according to the National Institute of Neurological 
and Communicative Disorders and Stroke and Related Disorders Association (McKhann, 
1984) and DSM-IV criteria for dementia of the Alzheimer type.  
The AD diagnosis was based on neuropsychological and clinical evaluation and was made by 
a consensus conference of psychiatrists and neuropsychologists prior to the metabolites 
measurements.  
The presence of relevant vascular cerebral damage was excluded for all study participants 
with AD by computed tomography or magnet resonance tomography and the Hachinsky 
Ischemic Score (score<4) (Wade and Hachinsky, 1986)  
As control subjects we recruited 98 consecutive patients (49 subjects aged ≥50 years and 49 
subjects aged <50 years) who underwent lumbar puncture at the Department of Neurology, 
University of Bonn, for different indications such as exclusion of CNS inflammation, 
exclusion of aneurysmal subarachnoid hemorrhage or exclusion of meningitis.  
 
Exclusion criteria included history or clinical evidence of cognitive decline, Mini-Mental 
State Examination scores≤26 (Folstein, 1975), regular intake of vitamin supplements, 
inflammatory diseases of the central nervous system, and other severe or unstable illness such 
symptomatic cardiac disease, renal or hepatic dysfunction, insulin-dependent diabetes 
mellitus, untreated thyroidal dysfunction, or excessive alcohol intake. In addition, patients 
with CSF samples indicating blood brain barrier disturbances or inflammatory signs, defined 
as CSF whole protein content >500mg/dl and more than 5 leucocytes/mm3, were excluded 
from both the AD group and controls. The study was approved by the local ethics committee. 
Written informed consent was obtained from all study participants or their legal 
representatives.  
Table 1 lists detailed information about the groups. 
 
CSF collection 
Diagnostic lumbar punctures were performed at the Departments of Neurology or Psychiatry, 
University of Bonn. A standardized technique with a 20G “atraumatical” spinal needle and a 
sitting or lying position for the patient was applied. CSF samples were immediately put on dry 
ice and then stored at -80 °C until assay procedures.  
 
Biochemical measurements and APOE genotyping: 
CSF was analyzed by tandem mass spectrometry for 5-MTHF, SAM, SAH and homocysteine 
as described previously (Struys, 2000; Smith, 2006. Homocysteine was measured in CSF by 
HPLC using fluorescence detection as previously described (Ubbink, 1991). Serum creatinine 
was measured during the clinical routine. Leukocyte genomic DNA was isolated with the 
Qiagen blood isolation kit (Qiagen, Hilden, Germany). The APOE genotype was determined 
as previously described (Hixson, 1991). 
 
Statistical analysis: 
Kommentar [P1]: Textbaustein 
Piotr 
All biomarker data were normally distributed according to the Kolmogorov-Smirnov test. 
Within groups, multivariate backward regression tests with P-tau181 and Aß1-42, 
respectively, as the dependent variables were performed to investigate for associations with 
the Hcys, SAM, SAH and 5-MTHF, and entering age, gender, creatinine, and presence or 
absence of APOE ε4 allele as further variables. The associations between P-tau181 and the 
SAM/SAH ratio, and between Aß1-42 and the SAM/SAH ratio were separately analyzed in 
backward regression models including age, gender, creatinine, and presence or absence of 
APOE ε4 allele. Additionally, Aß1-42 was included in all regression models with P-tau181 as 
the dependent variable, and P-tau181 in the models with Aß1-42 as the dependent variable. In 
a further step, the younger control subjects (age<50 years; n=49) were analyzed separately to 
investigate whether associations between the parameters of the homocysteine metabolism and 
CSF markers for AD can be observed in this subgroup or may be related only to older age. All 
statistical analyses were performed using the statistical analysis software package SPSS 14.0 
for Windows. 
 
 
Results: 
P-tau181 was associated with SAH (T=5.074; ß=0.490; p<0.001), 5-MTHF (T=-2.701; ß=-
0.273; p=0.010), gender (T=2.097; ß=0.227; p=0.042) and Aß1-42 levels (T=3.457; ß=0.345; 
p=0.001) in the control group (model: F1-45=15.494, p<0.001). Within the AD group (model: 
F1-27=6.056, p=0.001), SAH (T=3.685; ß=0.529; p=0.001) and Aß1-42 levels (T=-2.268; ß=-
0.319; p=0.031). The CSF SAM/SAH ratio was associated with P-tau181 levels (model: F1-
46=13.311, p<0.001; T=-2.575; ß=-0.319; p=0.013) only in the control group.  
When analyses were separately performed in the subgroup of younger controls, in the final 
model (F1-23=8.855, p<0.001) P-tau181 was associated with SAH (T=3.166; ß=0.441; 
p=0.004) and Aß1-42 levels (T=2.447; ß=0.339; p=0.022). In the control subjects aged ≥50 
years (model: F1-18=6.918, p=0.002), P-tau181 was associated with SAH (T=2.475; ß=0.394; 
p=0.023) and Hcys levels (T=3.217; ß=0.394; p=0.005). Furthermore, P-tau181 was 
associated with the SAM/SAH ratio in the younger (F1-28=11.344, p<0.001; T=-3.290; 
ß=0.477; p=0.003) and the older subgroups.  
The levels of Aß 1-42 were not significantly associated with the CSF concentrations of Hcys, 
SAM, SAH, 5-MTHF or the SAM/SAH ratio neither in the AD nor in the control group (not 
shown).  
 
 
Discussion: 
Despite substantial evidence from epidemiological studies that disturbed homocysteine 
metabolism increases the risk and contribute to the clinical course of AD, possible underlying 
pathophysiological mechanisms are not entirely explained. In the present study we found CSF 
metabolites of the homocysteine cycle to be associated with CSF P-tau181 levels, which 
suggest that alterations of the homocysteine metabolism in the central nervous system may 
contribute to increased tau phosphorylation, a hallmark of AD pathology. 
  
In both the AD and the control group we found strong associations of P-tau181 levels with 
SAH concentrations in the CSF. In addition, P-tau181 levels were associated with 5-MTHF 
CSF concentrations and the SAM/SAH ratio in the control group, and with Hcys levels in the 
subgroup of older control participants. Several studies have shown that alterations of the 
homocysteine metabolism may result in increased phosphorylation of the tau protein. The 
insufficient methylation of protein phosphatase 2A (PP2A), which depends on SAM as 
methyl group donor, and is necessary for efficient tau dephosphorylation was proposed as a 
possible mechanism leading to the accumulation of P-tau in AD (Vafai and Stock, 2002).  
As demonstrated in a study in neuroblastoma cells, incubation with SAH leads to reduced 
methylation of PP2A, which is associated with dose dependent enhanced tau phosphorylation 
and accumulation of P-tau (Sontag, 2007). Other studies showed that folate deprivation 
increases tau phosphorylation by homocysteine induced calcium influx and by inhibition of 
phosphatase activity in cultured cells, and enhances the brain levels of P-tau in mice (Chan, 
2008; Sontag, 2008). Furthermore, experimental in vivo homocysteine administration leads to 
increased brain SAH (Gharib 1983), and induces AD-like tau hyperphosphorylation in rat 
hippocampus by inactivating PP2A (Zhang, 2007).  
In humans, post mortem studies revealed reduced hippocampal PP2A mRNA expression 
(Vogelsberg-Ragaglia, 2001) and decreased PP2A methylation levels in the brains of patients 
with AD compared to controls (Sontag, 2004). In addition, the cerebral loss of PPMT (a 
specific metyltransferase which catalyze the PP2A methylation) closely paralleled the severity 
of tau pathology, but not the amyloid plaque burden (Sontag, 2004). In a previous CSF study 
in participants with different neurological diseases including 9 AD patients the authors 
reported significant correlations of SAH and folate levels with CSF P-tau181 (Obeid, 2007). 
Together with these studies, our findings strongly suggest that alterations of the homocysteine 
metabolism contribute to tau hyperphosphorylation, which is reflected by increased CSF 
concentrations of P-tau181. Furthermore, we observed this association not only in AD, but 
also in the cognitively healthy controls, and in particular in the subgroup of younger controls 
which suggests that homocysteine metabolism disturbance may become relevant for tau 
hyperphosphorylation decades before the first clinical signs of AD. This possibly contributes 
to the pathophysiological changes at pre-clinical disease stages, and may explain in part the 
finding of altered homocysteine metabolism as a risk factor of AD.  
 
Another central feature of the AD pathology is the cerebral aggregation and deposition of 
Aß1-42 in the form of amyloid plaques, which is paralleled by decreased CSF Aß1-42 
concentrations. In experimental studies, disturbed homocysteine metabolism has been linked 
to different possible mechanisms resulting in overproduction of Aß1-42. For example, 
reduced PP2A methylation after cell incubation with SAH was found to be associated with 
increased secretion of ß-secretase cleaved amyloid precursor protein fragments and Aß 
peptides (Sontag et al., 2004). Other studies have shown that homocysteine metabolism 
alterations i.e. resulting from B-vitamin and folate deficiency modify DNA methylation status 
with consequent enhance of presenilin1 and ß-secretase expression, which leads to increased 
Aß production in cell cultures (Scarpa, 2003; Fuso, 2005) and in mice (Fuso, 2008; Chan and 
Shea, 2007). 
In line with these findings, positive correlations between plasma homocysteine and plasma Aß 
levels have been reported in a sample of patients with AD, mild cognitive impairment, 
Parkinson’s Disease and healthy controls (Irizarry 2005). Furthermore, B-vitamins 
administration reduced the plasma levels of Aß in a study in older men (Flicker 2008). In a 
previous CSF study in participants with different neurological diseases, however, no 
association was found between homocysteine metabolism parameters and Aß1-42 levels 
(Obeid, 2007). In accordance with this later report, in our study the CSF levels of Aß 1-42 did 
not correlate with the CSF concentrations of Hcys, SAM, SAH and 5-MTHF, or the 
SAM/SAH ratio neither in the AD nor in the control group. These results do not support the 
hypothesis that disturbed homocysteine metabolism substantially contributes to increased 
cerebral Aß production. Possible explanations for the discrepancy between these findings in 
the CSF and the results of experimental and plasma studies may be that other mechanisms 
modifying the cerebral Aß production and clearance may have more important effects on the 
Aß1-42 CSF levels, and that plasma Aß levels does not accurately reflect CSF Aß 
concentrations (Mehta, 2001).  
 
The presence of the APOEε4 allele is a major risk factor for AD, and the APOE genotype was 
proposed to modify the links between disturbed homocysteine metabolism and 
neurodegenerative processes (Tchantchou, 2006; Chan and Shea, 2007). Some community-
based studies (Elias, 2008), but not all (Dufouil, 2003) have found that the presence of the 
APOEε4 allele influences the association between plasma homocysteine and cognitive 
performance in cognitively healthy subjects. Experimental studies demonstrated that baseline 
levels of brain SAM were lower in APOE knockout mice in comparison to control mice. 
Furthermore, alteration of the homocysteine metabolism induced by folate deficient diet was 
more pronounced, and associated with increased gamma-secretase activity, and higher Aß 
levels in the APOE knockout mice (Tchantchou, 2006; Chan and Shea, 2007). However, in a 
study including patients with AD, mild cognitive impairment, Parkinson’s Disease and 
healthy controls the presence of the APOEε4 allele did not influenced the association of 
plasma homocysteine with plasma Aß42 levels (Irizarry, 2005). In accordance with this 
report, in our study the presence or absence of the APOEε4 allele did not modified the 
associations of the metabolites with the CSF levels of Aß1-42 and P-tau181 in any group, 
which did not support the hypothesis that the presence of the APOEε4 allele may link the 
homocysteine metabolism alteration to neurodegeneration. 
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Table 1 : Subject characteristics 
 Controls (n=98) AD (n=54) 
Age (years):  mean (SD),  
range 
50.05 (16.84),  
16-81 
73.04 (7.69),  
56-92 
Gender (m/w): n 54/44 14/40 
APOEε4 (non-carrier/ carrier): n 79/17 17/37 
MMSE: mean  (SD),  
range 
29.71 (0.55),  
28-30 
21.33 (4.27),  
6-29 
Cr (mg/dl): mean (SD), range 0.86 (0.17), 0.58-1.43  0.84(0.17), 0.62-1.31 
Hcys (nmol/l): mean (SD),  
range 
72.13 (44.50),  
12.60-303.30 
71.89 (43.55),  
18.60-226.00 
5-MTHF (nmol/l): mean (SD),  
range 
41.49 (13.66),  
12.10-74.30 
37.65 (10.42),  
16.50-64.70 
SAH (nmol/l): mean (SD),  
range 
22.04 (6.70),  
10.60-49.00 
26.86 (6.18),  
12.60-41.60 
SAM (nmol/l): mean (SD),  
range 
204.90 (40.53),  
80.00-390.70 
192.63 (31.19),  
123.30-264.60 
SAM/SAH: mean (SD),  
range 
10.05 (3.36),  
3.39-19.97 
7.61 (2.39),  
3.52-14.62 
P-tau181 (pg/ml): mean (SD),  
range 
45.18 (17.82),  
8.00-101.57 
81.62 (33.55),  
29.40-182.10 
Aβ1-42 (pg/ml): mean (SD),  
range 
930.45 (245.43),  
327.00-1412.00 
420.07 (158.46),  
123.30-264.60 
 
SD : Standard-Deviation; MMSE : Mini-Mental State Examination; Cr : Creatinine; Hcys : 
Homocysteine; 5-MTHF : 5-methyltetrahydrofolate; SAH : S-adenosylhomocysteine; SAM : 
S-adenosylmethionine. 
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Fig. 1: Correlations between the concentrations of CSF P-tau181 and CSF SAH in (A) the 
control and (B) the AD group. 
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 Fig. 2: Correlations between the concentrations of CSF P-tau181 and CSF 5-MTHF in (A) 
the control and (B) the AD group. 
 
